The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) gamma-linolenic acid (GLA) and/or the pharmaceutically acceptable deri...

PURPOSE: A chewable tablet for oral administration, containing atomoxetine or a pharmaceutically acceptable salt thereof, a hydrophilic polymer, and an anionic polymer is provided to effectively block unpleasant taste (bitter taste, acrid taste) without a separate process or facility, and to enhance drug compliance. CONSTITUTION: A chewable atomoxetine tablet for oral administration contains 1 part by weight of atomoxetine or a pharmaceutically acceptable salt thereof, 0.01- 1 parts by weight of...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable de...

The present invention provides an efficient method for preparing atomoxetine in high yield. (R)-methylhydroxylaminopropanol compound of formula (II) in the present invention is used as an intermediate without the need for resolution processes.

The invention provides novel dosage forms of atomoxetine and its salts particularly atomoxetine hydrochloride including wax dosage forms press-coat dosage forms and sprinkle dosage forms and other novel dosage forms. The invention also provides sustained-release and pulsed-release dosage forms of atomoxetine and its salts. Methods of making novel atomoxetine dosage forms are given. Methods of treating senile dementias including Alzheimer\'s dementia attention deficit disorder and other neuropsyc...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivati...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivati...

The present invention relates to novel polymorphs of 4-hydroxy Atomoxetine hydrochloride and process for the preparation thereof. The present invention also relates to crystalline monohydrate and anhydrate forms of 4-hydroxy Atomoxetine hydrochloride.

The present invention provides an efficient method for preparing atomoxetine in high yield. (R)-methylhydroxylaminopropanol compound of formula (II) in the present invention is used as an intermediate without the need for resolution processes.

The present invention provides an efficient method for preparing atomoxetine in high yield. (R)-methylhydroxylaminopropanol compound of formula (II) in the present invention is used as an intermediate without the need for resolution processes.